艾滋病患者抗病毒治疗生存时间分析  

Survival Analysis on AIDS Patients After Antiviral Therapy

作　　者：王婉薇[1,2] 余世林[2] 于雪兰[2] 栾荣生[1] 

机构地区：[1]四川大学成都610041 [2]内江市疾病预防控制中心四川内江641100

出　　处：《预防医学情报杂志》2013年第3期216-220,共5页Journal of Preventive Medicine Information

摘　　要：目的了解内江市艾滋病患者抗病毒治疗后生存时间现状,探讨不同治疗方案及基线CD4+T淋巴细胞计数对生存时间的影响。方法利用国家艾滋病综合防治信息系统抗病毒治疗内江市治疗数据信息,使用SPSS 17.0进行相关分析。结果本研究纳入227例患者,截止到2011-12-31,共有40例研究对象死亡,其中92.5%(37/40)死于艾滋病相关疾病。含AZT方案/d4T方案患者生存率差异无统计学意义,基线CD4+T淋巴细胞计数不同,患者的生存期差异有统计学意义(χ2=10.631,P<0.01)。结论定期监测艾滋病感染人群的CD+4T淋巴细胞计数,定期随访观察他们的临床症状,早期对患者开展抗病毒治疗更有利于延长病人的生存时间。Objective To understand the survival time for AIDS patients after antiviral therapy and explore the influence of different treatment options and baseline CD4＋T count on survival time of the patients in Neijiang.Methods Data were collected from antiviral therapy of Neijiang derived from the National AIDS prevention and control information system,and further conducted correlation analysis using SPSS17.0 Results Totally 227 patients were enrolled and 40 of which died by December 31,2011,among which 92.5%（37/40） died of AIDS-related illnesses.There was no statistical difference in terms of survival rate between patients containing AZT and the ones containing d4T.The difference of the survival of the AIDS patients whose baseline CD4＋T lymphocyte count was different was statistically significant（χ2=10.631,P＆lt;0.01）.Conclusion Regular monitoring of CD＋4T lymphocyte count of the AIDS patients,regular follow-up observation of their clinical symptoms and starting antiviral treatment for patients early are more beneficial to prolong survival time of the patients.

关 键 词：抗病毒治疗 艾滋病 生存率 

分 类 号：R512.91[医药卫生—内科学]